Category Archives: Regenerative Medicine

Intensities of protein expression of markers are shown on viSNE map as spectrum colored dots, with low in blue, high in red. (Image: Bachmaier, et al. ACS Nano)

Using a protein nanoparticle they designed, scientists at the University of Illinois Chicago have identified two distinct subtypes of neutrophils and found that one of the subtypes can be used as a drug target for inflammatory diseases.

Neutrophils are a type of white blood cell that help fight infection, clear dead cell debris, and heal tissue injury. But for people with health conditions caused by chronic inflammation, like arthritis or Crohns disease, or excessive inflammation, like sepsis, the role of neutrophils may be deleterious. Neutrophils have been described in research as also contributing to tissue damage the double-edged sword of inflammation. Unfortunately, current drugs for inflammatory diseases that target neutrophils suppress all their effects, including their anti-infection and healing functions.

The UIC team is the first to characterize neutrophils into two subsets.

Understanding the differences between these neutrophil subsets opens the door for more research on treatments that address inflammatory diseases without increasing patients risks of infections, said study author Kurt Bachmaier, assistant professor in the department of pharmacology and regenerative medicine at the College of Medicine, who led the research.

Bachmaier and his colleagues first used the nanoparticle platform, formulated from a protein called albumin, to analyze how neutrophils from bone marrow, blood, and spleen and lung tissues interact with the nanoparticle. They found that some neutrophils brought the albumin nanoparticle into the cell through a process called endocytosis, while others didnt.

The scientists labeled the subtype that readily endocytosed the nanoparticle as ANP-high, for albumin nanoparticle high. The neutrophils that did not absorb the albumin nanoparticle were labeled as ANP-low.

Further investigation with the albumin nanoparticle showed that the subtypes have different cell surface receptors and that they are functionally distinct in their helpful capacities to kill bacteria and their harmful potential to promote inflammation. ANP-highneutrophils did not help to kill bacteria but produced inordinate amounts of reactive oxygen species and inflammatory chemokines and cytokines, which contribute to inflammatory disease.

Because the ANP-high neutrophils are also the ones that captured the nanoparticle, the scientists conducted clever experiments using the albumin nanoparticle to deliver drug treatments. They filled the nanoparticle with an anti-inflammatory drug and administered it to mice with sepsis. They found that the mice treated with the drug-loaded nanoparticle had reduced signs of tissue inflammation, but that the neutrophilic host-defense was preserved.

The albumin nanoparticle, which was filled with the drug, specifically bound to ANP-high neutrophils and unloaded their cargo into the cell, stopping it in its tracks, Bachmaier said.We found ANP-high neutrophils not only in mice but also in humans, opening the possibility of neutrophil subset-specific targeted therapy for human inflammatory diseases.

Science can be a bit like magic by targeting only the ANP-high neutrophils, we stopped the out-of-control inflammation while preserving the bacteria-fighting inflammation of these Janus-like cells, said senior author Asrar Malik, Schweppe Family Distinguished Professor and head of the department of pharmacology and regenerative medicine.

These findings are reported in the article Albumin Nanoparticle Endocytosing Subset of Neutrophils for Precision Therapeutic Targeting of Inflammatory Tissue Injury, which is published in ACS Nano, a scientific publication of the American Chemical Society and the primary nanotechnology journal.

Co-authors of the article are Andrew Stuart, Amitabha Mukhopadhyay, Sreeparna Chakraborty, Zhigang Hong, Li Wang, Yoshikazu Tsukasaki, Mark Maienschein-Cline, Balaji Ganesh, Prasad Kanteti and Jalees Rehman.

Here is the original post:
Newly identified neutrophil subset is a promising therapeutic target | UIC Today - UIC Today

Pune, April 04, 2022 (GLOBE NEWSWIRE) -- Stem cells refer to the undifferentiated biological cells that differentiate into specialized cells and divide to produce more stem cells. They are found in multicellular organisms and are of two types mainly embryonic stem cells and adult stem cells. These cells are present in areas in the body such as bone marrow, adipose tissue, and blood. Stem cells are also taken from umbilical cord blood. The stem cell population in the body is maintained through two processes, which include obligatory asymmetric replication and stochastic differentiation. Stem cells play an important role in the natural healing process of the body and introduction of stem cells has shown positive results in the treatment of many diseases such as cancer. The significance of stem cell assays lies in the fact that they are used for various processes such as viability or cytotoxicity studying, isolation and purification of stem cells, cell identification, cell proliferation, and cell differentiation for research purposes. In the case of stem cell transplant, initially, the embryonic stem cells are specialized into necessary adult cell type. Then, these cells are used to replace the tissue that is damaged due to any disease or injury.

The growth of thestem cell assays market corresponds with that of the biotechnology and biopharmaceutical industries, as these form significant end users for stem cell research products. The continuation of this trend the growth of the end-user base has compelled a number of companies to launch new products and invest in stem cell-based therapies. The growing incidence of cancer is increasing across the globe due to the rise in the aging population and changing lifestyle habits. This in turn, is accelerating the demand for anticancer drugs and therapies globally. The growing prevalence of various diseases such as cancer and cardiovascular diseases and the potential of stem cell therapy in the management of these diseases is projected to boost the growth of the Stem Cell Assay Market. Stem cell transplant replaces the neurons damaged by spinal cord injury, Alzheimers disease, and stroke. These factors are expected to drive the growth of the Stem Cell Assay Market.

Get a Sample Copy of the Report https://www.marketdatacentre.com/sample/8

The development in embryonic & adult stem cell assay will be beneficial to the global market. The increasing adoption of stem cell therapies has significantly helped the market to grow substantially. The continuously increasing healthcare expenditure and funding by several governments and private players in the field of stem cell research have boosted the market. Moreover, technological advancement in the instruments has driven the demand for stem cell assays in the market.Emergence of microfluidics in stem cell research, high growth potential of single stem cell analysis sequencing, and untapped potential in emerging markets offer favourable growth opportunities.

The Global Stem Cell Assay Market is segmented on the basis of Product, Cell types, Application, Assay, and region. Based on product market is segmented into Instruments, Reagents and kits. The instruments segment accounted for the largest share of global Stem Cell Assay Market. Some of the major factors driving the growth of this segment include ongoing technological innovations in stem cell instruments and the rising number of stem cell research activities.

Based on cell types market is divided into Adult Stem Cells (Induced Pluripotent Stem Cells, Mesenchymal Stem Cells, Neural Stem Cells, Hematopoietic Stem Cells, and Umbilical Cord Stem Cells) and Human Embryonic Stem Cells. By application, the market is segmented into regenerative medicine and therapy development, drug discovery and development, and clinical research. The regenerative medicine and therapy development segment accounted for the largest share of the global Stem Cell Assay market. The increasing demand for stem cells in the development of various types of cell therapies and growing regenerative medicine industry across the world are factors driving this market segment.

Based on Assay, The market is segmented into Cell Identification Assays, Viability Assays, Apoptosis Assays, Isolation & Purification Assays, and Others. The viability segment holds the largest market share during the forecast period. The factors that can be attributed to the widespread use of viability assays in stem cell research activities. Based, on the end user the market is divided into Government research institutes, Private Research Institutes and Industry Research.

Regional Analysis

Stem cell assay market is regionally segmented into North America, Asia-Pacific, Europe, and Rest of the World. North America followed by Europe had the biggest market for Stem cell based assays. In North America the large share of the geographical segment is attributed to factors such as the increasing incidence of chronic diseases and improved life sciences, research infrastructure and increasing funds for R&D in that region.

The European market is not far behind North America and is projected to show promising growth in the upcoming period. Factors such as increasing consciousness regarding cell based assays and increased adoption of R&D activities is propelling the markets growth rate.

Asia-Pacific market is expected to grow in the upcoming years. Growth in Asia-Pacific is due to rising infrastructural developments, growing funds in R&D by various public and private organizations is enhancing the market. The growing no. of Cancer cases, rising toxicity for examination and drug identification are escalating the stem cell assays market.

Speak to Our Research Analyst https://www.marketdatacentre.com/analyst/8

COMPANY PROFILES (Business Overview, Products/Services Offered, Financial Performance, R&D Intensity, Marketing & Sales Intensity, Recent Developments, Analyst Corner)*

At MDC Research, we offer research solutions to help businesses break the barriers of doubt or uncertainties when they plan to expand their growth. Our researchers compile data and information that help chief executive officers decide which growth opportunities in a market to pursue.

MDC Research is known for conducting well-researched reports, and the expertise of our researchers contributes to the outstanding quality of our reports. MDC Research enables businesses to make impactful decisions by blending innovation and analytical thinking. Our unique blend of these two skills assures you access to the most complete and up-to-date information about your industry.

MDC Research has a wealth of experience using the latest methodologies to develop reports for a wide range of clients in diverse markets. Our commitment to delivering high-quality research and creating innovative reports is one of the reasons why MDC Research is such a trusted name in the business world today.

Buy the Premium Report https://www.marketdatacentre.com/checkout/8

Recent Developments

GE Healthcare inaugurated a new testing centre to enhance its research and manufacturing capabilities.

Danaher Company launched ClearLLAb 10C systems for flow cytometry labs.

PerkinElmer completed acquisition of Cisbio Bioassays.

Read Overview of the Report https://www.marketdatacentre.com/stem-cell-assay-market-8

About MDC:

Market Data Centre (Subsidiary of Yellow Bricks Global Services Private Limited)

Market Data Centre offers complete solutions for market research reports in miscellaneous businesses.These decisions making process depend on wider and systematic extremely important information created through extensive study as well as the most recent trends going on in the industry.The company also attempts to offer much better customer-friendly services and appropriate business information to achieve our clients ideas.

Read more:
Stem Cell Assay Market | Viability/Cytotoxicity Assay Segment Estimated to Account for the Largest Share - Here's Why - MDC Research - GlobeNewswire

Human ES cell derived RASC (respiratory airway secretory cell) transitioning to an Alveolar type 2 cell over time in culture

PHILADELPHIA A new type of cell that resides deep within human lungs and may play a key role in human lung diseases has been discovered by researchers at the Perelman School of Medicine at the University of Pennsylvania.

The researchers, who report their findings today in Nature, analyzed human lung tissue to identify the new cells, which they call respiratory airway secretory cells (RASCs). The cells line tiny airway branches, deep in the lungs, near the alveoli structures where oxygen is exchanged for carbon dioxide. The scientists showed that RASCs have stem-cell-like properties enabling them to regenerate other cells that are essential for the normal functioning of alveoli. They also found evidence that cigarette smoking and the common smoking-related ailment called chronic obstructive pulmonary disease (COPD) can disrupt the regenerative functions of RASCshinting that correcting this disruption could be a good way to treat COPD.

COPD is a devastating and common disease, yet we really dont understand the cellular biology of why or how some patients develop it. Identifying new cell types, in particular new progenitor cells, that are injured in COPD could really accelerate the development of new treatments, said study first author Maria Basil, MD, PhD, an instructor of Pulmonary Medicine.

COPD typically features progressive damage to and loss of alveoli, exacerbated by chronic inflammation. It is estimated to affect approximately 10 percent of people in some parts of the United States and causes about 3 million deaths every year around the world. Patients often are prescribed steroid anti-inflammatory drugs and/or oxygen therapy, but these treatments can only slow the disease process rather than stop or reverse it. Progress in understanding COPD has been gradual in part because micethe standard lab animalhave lungs that lack key features of human lungs.

In the new study, Morrisey and his team uncovered evidence of RASCs while examining gene-activity signatures of lung cells sampled from healthy human donors. They soon recognized that RASCs, which dont exist in mouse lungs, are secretory cells that reside near alveoli and produce proteins needed for the fluid lining of the airway.

With studies like this were starting to get a sense, at the cell-biology level, of what is really happening in this very prevalent disease, said senior author Edward Morrisey, PhD, the Robinette Foundation Professor of Medicine, a professor of Cell and Developmental Biology, and director of the Penn-CHOP Lung Biology Institute at Penn Medicine.

Observations of gene-activity similarities between RASCs and an important progenitor cell in alveoli called AT2 cells led the team to a further discovery: RASCs, in addition to their secretory function, serve as predecessors for AT2 cellsregenerating them to maintain the AT2 population and keep alveoli healthy.

AT2 cells are known to become abnormal in COPD and other lung diseases, and the researchers found evidence that defects in RASCs might be an upstream cause of those abnormalities. In lung tissue from people with COPD, as well as from people without COPD who have a history of smoking, they observed many AT2 cells that were altered in a way that hinted at a faulty RASC-to-AT2 transformation.

More research is needed, Morrisey said, but the findings point to the possibility of future COPD treatments that work by restoring the normal RASC-to-AT2 differentiation processor even by replenishing the normal RASC population in damaged lungs.

The research was supported by the National Institutes of Health (HL148857, HL087825, HL134745, HL132999, 5T32HL007586-35, 5R03HL135227-02, K23 HL121406, K08 HL150226, DK047967, HL152960, R35HL135816, P30DK072482, U01HL152978), the BREATH Consortium/Longfunds of the Netherlands, the Parker B. Francis Foundation, and GlaxoSmithKline.

Penn Medicineis one of the worlds leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of theRaymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nations first medical school) and theUniversity of Pennsylvania Health System, which together form a $9.9 billion enterprise.

The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according toU.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $546 million awarded in the 2021 fiscal year.

The University of Pennsylvania Health Systems patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Centerwhich are recognized as one of the nations top Honor Roll hospitals byU.S. News & World ReportChester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nations first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.

Penn Medicine is powered by a talented and dedicated workforce of more than 52,000 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2021, Penn Medicine provided more than $619 million to benefit our community.

See original here:
Penn Researchers Discover New Cell Type in Human Lung with Regenerative Properties - Penn Medicine

CANTON, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis, a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that the latest advanced wound care research on its PuraPly AM, Affinity, Apligraf, NuShield, Novachor and Organogenesis Physician Solutions product lines will be showcased at the 2022 Symposium on Advanced Wound Care (SAWC) Spring Conference held April 6-10, 2022 in Phoenix, Arizona.

As a leading sponsor of this years conference, we are excited to share new research on our innovative product portfolio and hear from other thought leaders about advances in wound care, said Katie Mowry, Assistant Vice President, Research and Development for Organogenesis.

Attendees of this year's event are encouraged to visit the Organogenesis-supported breakfast symposium, "Investigating the Reliability and Transferability of Current RCT Based on Real-World Evidence" held Thursday, April 7, 2022 from 7:30 to 9:00 a.m. MST in room 224 at the Phoenix Convention Center. This panel discussion features Vickie R. Driver, DPM, MS, FACFAS FAAWC, Robert S. Kirsner, MD, PhD, FAAD, William Marston, MD, and Oscar M. Alvarez, PhD, CCT, FAPWCA, and will discuss how randomized controlled trials (RTCs) based on real-world evidence translates to evaluating wound care therapies.

The Organogenesis-sponsored Innovation Theatre lunch, Practical Utilization of Skin Substitutes for Chronic Wounds Using Prognostic Patient Indicators will be held Thursday, April 7, 2022 from 12:00 to 1:30 p.m. MST in room 224. This lunch will feature a presentation by Andrew J. Rader, DPM, FAENS, FACFAOM, FAPWCA, FACCWS of Memorial Hospital Wound Care and Nicholas Todd, DPM, FACFAS of Palo Alto Medical Foundation, who will discuss the use of prognostic patient indicators to determine the appropriate course of action for treating chronic wounds.

Attendees are encouraged to visit the Organogenesis exhibit hall booth (#703) to learn more about the latest advanced wound care products and latest studies. Organogenesis tissue regeneration specialists will be available to discuss the full portfolio of Organogenesis solutions that address wounds from head to toe.

The booth will be open during the following hours:

POSTER PRESENTATIONS OF INTEREST INCLUDE:

A Single Center Pilot Study Investigating the Effects of a Native Cross-Linked Extra Cellular Matrix with PHMB Antimicrobial Barrier to Manage Chronic Lower Extremity Wounds Exhibiting Bacterial Contamination as Determined by a Novel Violet-Light Imaging SystemWindy Cole, DPM, CWSP1, Janina Krumbeck, PhD

An Alternative Approach to the Management of Wounds Secondary to Diagnosis or Treatment of Skin CancersDaniel Kapp, MD, Laura Pfendler, PT, DPT, CWS

Real World Data Analyses of a Bilayered Living Cellular Construct and a Cryopreserved Placental Membrane for Use in Pressure InjuriesOscar M. Alvarez, PhD, Michael L. Sabolinski, MD

Real World Data Analyses of a Bilayered Living Cellular Construct and a Cryopreserved Cadaveric Skin Allograft for Use in Pressure InjuriesOscar M. Alvarez, PhD, Michael L. Sabolinski, MD

ABSTRACTS OF INTEREST INCLUDE:

Characterization of a Micronized Native Collagen Wound Matrix And Its Effectiveness In a Swine Full-Thickness Wound Healing Model Justin T. Avery, Vivek P. Raut, and Katie C. Mowry

Hypothermic Storage of Amnion and Chorion Membranes Retain Native Tissue CharacteristicsKatrina A. Harmon Ph.D.1 and Katie C. Mowry Ph.D.1

Robust Durability and Resistance to Degradation of a Native Type I Collagen Matrix with PHMB in vitroKatrina A. Harmon, Ph.D.1 and Katie C. Mowry Ph.D.1

About Organogenesis Holdings Inc.Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts for future events. Forward-looking statements may be identified by the use of words such as "will," "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," "extend," "continue" and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. Important factors that could cause actual outcomes to differ materially from those indicated by these forward-looking statements include risks and uncertainties described in the Companys Annual Report on Form 10-K for the year ended December 31, 2021. Organogenesis cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only to the date of this release, and Organogenesis undertakes no obligations to update or revise these statements, except as may be required by law.

Continued here:
Organogenesis Showcases Latest Advanced Wound Care Innovations and Research at SAWC Spring 2022 Conference - GlobeNewswire

DUBAI, United Arab Emirates, The global 3D cell culture market stands at a net worth of US$ 1.15 Bn in 2022, and is predicted to surge ahead at a CAGR of 9.8% over the forecast period to attain a valuation of US$ 2.67 Bn by 2031.

3D cell culture is a suitable alternative in translational and regenerative medicine since its represents a new, advanced, and robust platform for the investigation of complex biological procedures. 3D cell culture is projected to extend to various sectors of scientific research.

Request a report sample to gain comprehensive insights at https://www.futuremarketinsights.com/reports/sample/rep-gb-2843

The 3D cell culture market revenues surpassed US$ 778 million in 2018, as per a new FMI study. The market is estimated to grow at 7.8% y-o-y in 2019; key factors responsible for the projected market growth include,

While 2D cell culture revolutionized the research efforts in stem cells, tissue engineering, and molecular biology, 3D cell culture has pushed the boundaries of traditional 2D cell culture technique with functional superiority. As the R&D efforts continue to rise in a bid to investigate the cause of different diseases and improve human health, 3D cell culture is set to remain a highly sought-after technique in the coming years, says FMI.

The FMI study finds that scaffold-based 3D cell culture techniques are highly preferred over scaffold-free 3D cell culture. Owing to the significant adoption of scaffold-based 3D cell culture, the study finds that this technique garnered over 81% of the global market revenues.

Scaffold-based 3D cell culture techniques deliver researchers with additional functional operations in terms of material natural or synthetic and different mechanical properties.

The technique uses either hydrogel-based support or polymeric hard material based support. Both types of supports find equivalent penetration in terms of application, however revenues garnered from polymeric hard material based support are higher.

According to the study, revenues of polymeric hard material based support held over half the scaffold-based 3D cell culture technique revenues in 2018 and the trend is expected to continue in the future.

For any Queries Related with the Report, Ask an Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-2843

Application of 3D Cell Culture in Cancer Research Prominent

The FMI study estimates that 3D cell culture application in cancer research accounted for over 31% of the 3D cell culture market revenues in 2018. Cell culture is an integral part of cancer drug discovery practices. Greater strides are underway in the field to precisely characterize the diseases and develop advanced tumor cell lines using 3D cell culture techniques.

2D culture lines are considered as a standard for in vitro pre-clinical cancer treatment screening. However, more recently, the field is turning to 3D cell culture techniques to implement an ideal experimental model that mimics the human body environment to its best.

Stem cell technology is another lucrative field for 3D cell culture market. According to the FMI study, application in stem cell technology accounted for over one-fourth of the 3D cell culture market revenues in 2018. While 2D cell culture posed challenges of scalability in stem cell technology, apart from a few challenges, 3D cell culture has provided greater density and multi-fold expansion of the culture system in stem cell technology. Other fields that utilize 3D cell culture techniques are tissue regeneration, regenerative medicine, and drug discovery.

We Offer tailor-made Solutions to fit Your Requirements, Request Customization @ https://www.futuremarketinsights.com/customization-available/rep-gb-2843

Biotechnology and Pharmaceutical Industries - Prominent End-Users

The study reveals that the biotechnology and pharmaceutical industries were accounted for over one-fifth of the global 3D cell culture market revenues in 2018. Buoyancy in the biotechnology and pharmaceutical industries can be profitable for the 3D cell culture market in the coming years and over 9% growth is projected in 2019 over 2019.

Academic research institutes are the second prominent end-users of 3D cell cultures wherein they accounted for over one-fourth of the global 3d cell culture revenues in 2018. Government funding in cancer research projects carried out at academic institutes and organizations has increased significantly, thereby supporting the investments in advanced technologies including 3D cell culture techniques.

Explore FMIs Extensive ongoing Coverage on Healthcare Domain

Pure Red Cell Aplasia Market - Pure red cell aplasia is a type of rare disorder related to the production of blood in the body. Spongy tissue between bone marrow fails to produce sufficient blood for the body leading to anaemic conditions.

Mantle Cell Lymphoma Market - Mantle cell lymphoma (MCL) is a blood cancer that is rare and occurs due to the too much growth of lymphocytes. Mantle cell lymphoma occurs as a result of the formation of tumors in the lymph nodes, which enters the blood and spreads to the spleen, bone marrow, liver and digestive tract.

Insect cell lines Market - Tissue culture is the in-vitro procedure for culturing tissues aseptically using growth medium. Insect cell culture is a special media used for production of vaccines, virus like particles and recombinant proteins.

About Future Market Insights (FMI)

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, and has delivery centers in the UK, U.S. and India. FMI's latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:

Future Market Insights,1602-6 Jumeirah Bay X2 Tower,Plot No: JLT-PH2-X2A,Jumeirah Lakes Towers, Dubai,United Arab EmiratesFor Sales Enquiries: sales@futuremarketinsights.comWebsite: https://www.futuremarketinsights.com/Report: https://www.futuremarketinsights.com/reports/3d-cell-culture-market

Read the original post:
3D Cell Culture Market are Predicted to Increase at a Positive CAGR Of 9.8% from 2022 to 2031 - Comprehensive Research Report by FMI - BioSpace

Kenneth Research, in its repository of market research reports, has recently added a report titledRegenerative Medicine Market, that emphasizes on the recent market trends and opportunities available for the growth of the market for the forecast period 2022-2031. The growth of the Regenerative Medicine Market can be attributed to the increasing health spending by nations across the globe, and for the rapid innovations observed in the medical sector. According to a report by the World Health Organization (WHO), the total health spending is growing with an annual average rate of 6% in the low- and middle-income nations, and close to 4% in the high-income countries. Further, in the year 2016, the expenditure made on health reached close to 10% of the GDP of the world and crossed a value of USD 7 trillion.

U.S. Market recovers fast; In a release on May 4th 2021, the U.S. Bureau and Economic Analsysis and U.S. Census Bureau mentions the recovery in the U.S. International trade in March 2021. Exports in the country reached $200 billion, up by $12.4 billion in Feb 2021. Following the continuous incremental trend, imports tallied at $274.5 billion, picked up by $16.4 billion in Feb 2021. However, as COVID19 still haunts the economies across the globe, year-over-year (y-o-y) avergae exports in the U.S. declined by $7.0 billion from March 2020 till March 2021 whilest imports increased by $20.7 billion during the same time. This definitely shows how the market is trying to recover back and this will have a direct impact on the Healthcare/ICT/Chemical industries, creating a huge demand for Regenerative Medicine Market products.

Download Sample PDF of this Report :-https://www.kennethresearch.com/sample-request-10070801

The Regenerative Medicine Market report provides an in-depth analysis of the Healthcare & Pharmaceuticals during the forecast period 2017-2026 which consists of the industry overview including the market size, volume, growth rate and recent trends and developments in the market based on historical and current data. The report covers detailed information about the key players, market segments, growth drivers and restraints in the industry. The report delivers an insight into the Regenerative Medicine Market which allows our clients to make informed decisions regarding the growth of their businesses.

The Regenerative Medicine Market is anticipated to reach over USD 79.23 billion by 2026 according to a new research published by Polaris Market Research. In 2017, the cell therapy dominated the global Regenerative Medicine market, in terms of revenue. North America is expected to be the leading contributor to the global market revenue in 2017.Regenerative medicine is a branch of medicine that regrows, and repairs the damaged cells in the human body. These medicines include the use of stem cells, tissue engineering, that further helps in developing new organ that function smoothly. These medicines have the caliber of developing an entire organ as these cells are multipotent. The cells are majorly isolated from bone marrow, and umbilical cord blood.

Request Free Sample Copy :-https://www.kennethresearch.com/sample-request-10070801The regenerative medicine market is primarily driven by the increasing number of individuals suffering from cancer, rising need to monitor and treating these chronic diseases in the limited time. Furthermore, stringent government policies, proper reimbursement policies, and increasing government healthcare expenditure for developing healthcare infrastructure to also boost the market growth in coming years. Also, rising number of organ transplantation, and increasing number of products in pipeline that are waiting for approval create major opportunity for the regenerative medicines in the coming years. However, some of the ethical and religious concerns for the use of stem cells, and lack of proper regulatory for the approval of various drugs would impede the market growth during the forecast period.

North America generated the highest revenue in the Regenerative Medicine market in 2017, and is expected to be the leading region globally during the forecast period. Increasing number of patients suffering from chronic diseases, improved healthcare infrastructure and health facilities, accessibility of healthcare facilities, are the primary factors driving the market growth in this region. While, Asia Pacific to be the fastest growing region in the coming years. The growth in this region is majorly attributed to the developing healthcare infrastructure of the countries like India, & China, and rising awareness for the use of regenerative medicines as an effective treatment option for chronic diseases.

The key players operating in the Regenerative Medicine market include Organogenesis Inc., Vericel Corporation, Osiris Therapeutics, Inc., Stryker Corporation, and NuVasive, Inc., Medtronic Plc., Acelity, Cook Biotech Inc., Integra LifeSciences, and C.R. Bard. These companies launch new products and collaborate with other market leaders to innovate and launch new products to meet the increasing needs and requirements of consumers

Request For Full Report-https://www.kennethresearch.com/sample-request-10070801

Table of Contents1. Overview and Scope1.1. Research goal & scope1.2. Research assumptions1.3. Research Methodology1.3.1. Primary data sources1.3.2. Secondary data sources1.4. Key take-away1.5. Stakeholders2. Executive Summary2.1. Market Definition2.2. Market Segmentation3. Regenerative Medicine Market Insights3.1. Regenerative Medicine Industry snapshot3.2. Regenerative Medicine Ecosystem analysis3.3. Regenerative Medicine Market Dynamics3.3.1. Regenerative Medicine Market Forces3.3.1.1. Regenerative Medicine Market Driver Analysis3.3.1.2. Regenerative Medicine Market Restraint/Challenges analysis3.3.1.3. Regenerative Medicine Market Opportunity Analysis3.4. Industry analysis Porters five force3.4.1. Bargaining power of supplier3.4.2. Bargaining power of buyer3.4.3. Threat of substitute3.4.4. Threat of new entrant3.4.5. Degree of competition3.5. Regenerative Medicine Market PEST Analysis3.6. Regenerative Medicine Market Value Chain Analysis3.7. Regenerative Medicine Industry Trends3.8. Competitive Ranking Analysis

Read More-https://www.kennethresearch.com/report-details/regenerative-medicine-market/10070801

About Kenneth Research

Kenneth Research provides scheduled syndicated reports that help industry professionals and organizations decipher market trends to take significant decisions and plan strategies. We cater to a wide range of industries including healthcare & pharmaceuticals, ICT & telecom, automotive & transportation, energy & power, chemicals, FMCG & food, aerospace & defense, among others. Our research team ensures to track and analyze the industry on a regular basis to offer strategic business consultancy services on a global level. We, at Kenneth Research are adept at capturing descriptive insights on crucial topics to help our clients make their informed decisions.Contact Us

Kenneth Research

Email : [emailprotected]

Phone: +1 313 462 0609

- New trending Reports

Cryotherapy MarketOrthopedic Implants MarketScaffold Technology MarketMalaria Vaccines MarketCardiac Rhythm Management (CRM) Devices MarketCell Banking Outsourcing MarketMedical Tourism Market

Follow this link:
Regenerative Medicine Market Size 2022 Share, Growth By Top Company, Business Opportunity, Regional Analysis, Application, Driver, Trends &...

CHICAGO, April 5, 2022 /PRNewswire/ -- According to the new market research report "Exosome Research Market by Product and services (Kits, Reagents, Instrument), Indication (Cancer, Infectious Diseases), Application (Biomarkers, Vaccines), Manufacturing Services (Stem cell, Dendritic cell-derived), End User - Global Forecast to 2026", published by MarketsandMarkets, the global market is projected to reach USD 661 million by 2026 from USD 144 million in 2021, at a CAGR of 35.6% during the forecast period.

Browse in-depth TOC on"Exosome Research Market"

229 Tables 32 Figures191 Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=224782498

The growth of this market is driven by factors such as the rising funding for life sciences research, the high global prevalence of cancer, and the increasing interest in exosome-based procedures. However, the dearth of skilled professionals is a major factor that is expected to restrain the growth of this market to a certain extent in the coming years.

Kits & Reagents segment accounted for the largest share of exosome research market

Based on product and service, the exosome research product market is segmented into kits & reagents, instruments, and services. The kits & reagents segment is further divided into antibodies, isolation, purification, quantitation kits & reagents, and other kits & reagents. Most exosome antibodies presently commercialized in the market cannot recognize exosome-associated antigens with the required specificity and sensitivity. This has propelled several companies to develop an array of polyclonal and monoclonal antibodies against common, disease-specific exosome-based markers. This is expected to make significant contributions to the kits & reagents market in the next few years.

Cancer segment accounted for the largest share of the exosome research market

Based on indication, the exosomes market is categorized into cancer, neurodegenerative diseases, cardiovascular diseases, infectious diseases, and other indications. The exosome research product market for cancer is segmented into lung cancer, prostate cancer, breast cancer, colorectal cancer, and other cancers. The large share is attributed to the high demand for exosome research products & services in lung cancer management. The exosomes secreted by tumor cells promote tumor progression, survival, invasion, and angiogenesis. Hence, the analysis of exosomes isolated from the blood or other body fluids of cancer patients could provide insights into cancer cell biology and serve as noninvasive predictive biomarkers for early detection, progression, and metastasis.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=224782498

Biomarkers segment accounted for the largest share of the exosome research market

Based on application, the exosome research product market is segmented into biomarkers, vaccine development, tissue regeneration, and other applications. Exosomes can be isolated from easily attainable biofluids, including blood, urine, and saliva; this has supported their use as biomarkers in disease management. Exosomes are also being used in developing vaccines against the COVID-19 virus, which accounts for the high growth rate of the vaccine development segment.

Academic & Research Institutes segment accounted for the largest share of exosome research market

Based on end user, the market is segmented into academic & research institutes, hospital & clinical testing laboratories, and pharmaceutical & biotechnology companies. There has been increasing demand for exosome research in the past few years due to their potential in disease diagnosis and their emerging role as intercellular messengers. This has piqued the interest of academic research professionals, contributing to the dominance of the academic & research institutes end-user segment in the market.

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=224782498

North America accounted for the largest share of the exosome research market

Based on region, the exosome research product market is segmented into North America, Europe, the Asia Pacific, and the Rest of the World. North America accounted for the largest share of the market. The US is the key revenue contributor to the North American market. The high prevalence of cancer coupled with the increasing demand for early and effective disease diagnosis and treatment is the key factor driving market growth in the US.

The prominent players operating in the exosome research market are Thermo Fisher Scientific (US), Bio-Techne (US), Lonza (Switzerland), QIAGEN N.V. (Germany), Miltenyi Biotec (US).

Browse Adjacent Markets: Biotechnology Market ResearchReports & Consulting

Browse Related Reports:

Stem Cell Therapy Market by Type (Allogeneic, Autologous), Therapeutic Application (Musculoskeletal, Wound & Injury, CVD, Autoimmune & Inflammatory), Cell Source (Adipose tissue, Bone Marrow, Placenta/Umbilical Cord) - Global Forecasts to 2026

https://www.marketsandmarkets.com/Market-Reports/stem-cell-technologies-and-global-market-48.html

Regenerative Medicine Market by Product (Cell Therapies (Autologous, Allogenic), Stemcell Therapy, Tissue-engineering, Gene Therapy), Application (Wound Care, Musculoskeletal, Oncology, Dental, Ocular), Geography - Global Forecast to 2025

https://www.marketsandmarkets.com/Market-Reports/regenerative-medicine-market-65442579.html

About MarketsandMarkets

MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish MehraMarketsandMarkets INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA: +1-888-600-6441Email: [emailprotected] Research Insight: https://www.marketsandmarkets.com/ResearchInsight/exosome-research-product-market.aspVisit Our Web Site: https://www.marketsandmarkets.comContent Source: https://www.marketsandmarkets.com/PressReleases/exosome-research-product.asp

SOURCE MarketsandMarkets

More:
Exosome Research Market worth $661 million by 2026 - Exclusive Report by MarketsandMarkets - PR Newswire

When Axiom Space launches its historic mission to the International Space Station, count on Mayo Clinic researchers to be paying close attention.

The flight, scheduled to take off Friday, will be the first all-civilian mission to the ISS. It will also represent a rare opportunity for Mayo researchers and scientists to study the crew on board as they travel through space.

Mayo is working with the crew to study signs of senescence in the crew, a process (and this is Mayos language) where a cell ages and stops dividing, but doesn't die, so it builds up in tissues throughout the body.

Looking for signs of senescence, according to Mayo, could help inform longer-haul trips such as a potential mission to Mars.

"The Mars mission may be very difficult to accomplish, unless we can find ways to monitor for senescent cell burden," saidDr. James Kirkland, director ofMayos Robert and Arlene Kogod Center on Aging.

Additionally, research will be conducted byDr. Andre Terzic, director of Mayos Center for Regenerative Medicine. Terzic, according to a Mayo, will be studying how to better safeguard the heart for space travel.

The Axiom Mission 1 is scheduled to launch from a SpaceX Falcon 9 rocket at NASAs Kennedy Space Center in Florida on Friday at 10:17 a.m. CT.

During their 10-day mission, the crew will spend time conducting outreach and commercial activities, in addition to their research, according to Axiom. The mission is the first of several proposed flights into space as part of the companys goal of building the first private space station.

The four civilian astronauts on the flight will be Michael Lpez-Alegra as commander; real-estate magnate and acrobatic pilot Larry Connor as pilot; and music and sustainability entrepreneur Mark Pathy, and investor and former Israel Air Force pilot Eytan Stibbe as mission specialists.

"The net result is this will benefit, if done correctly, all mankind," said Connor, a Mayo benefactor, according to the news release.

Axiom Space plans to stream the launch live online.

Cover photo courtesy Axiom Space

See more here:
Space research now in Mayo's orbit - Med City Beat

VALENCIA, Calif. and MELBOURNE, Australia, April 04, 2022 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today that fifteen presentations highlighting the clinical and cost-savings benefits of the RECELL Autologous Cell Harvesting Device (RECELL System) for the treatment of burn wounds will be shared at the American Burn Association (ABA) Annual Meeting. The conference will be held in Las Vegas, April 5-8, and will bring together more than 2,000 multi-disciplinary burn care professionals from across the globe to discuss burn care and the latest research related to burn injuries.

The depth and breadth of the RECELL System data being presented at the American Burn Association Annual Meeting highlights the impact this platform is having on the treatment protocol for burn injuries, said Dr. Mike Perry, Chief Executive Officer of AVITA Medical. Given the substantial and growing body of data supporting the efficacy of the RECELL System for treatment of burn wounds, coupled with the real-world treatment of more than 15,000 patients globally, we look forward to building on this strong track record to expand use of the RECELL System to encompass broader indications, including soft-tissue repair and vitiligo, following the completion of our clinical trials and approval by the FDA.

RECELL System PresentationsIn the U.S., the RECELLSystem is indicated for the treatment of acute thermal burn wounds in patients 18 years of age and older or application in combination with meshed autografting for acute full-thickness thermal burn wounds in pediatric and adult patients. Physician-initiated research beyond the FDA approved indicationis not sponsored by AVITA Medicaland contains independentdata.

The RECELL System is indicated in the U.S. for treatment of acute thermal burns. The frequency of burn-related injuries and the cost of treatment are high. The Centers for Disease Control and Prevention (CDC) reported that 486,000 patients receive emergency medical treatment for burns annually. Burn injuries result in approximately 3,400 deaths each year, the third-leading cause of accidental home injury deaths. Burns covering up to 90 percent of a persons body surface area, once considered fatal injuries, have become survivable with appropriate treatment. Although split-thickness autografts are the current standard treatment, grafting is often associated with significant donor site pain, delayed healing and scarring.

ABOUT AVITA MEDICAL, INC.AVITA Medical is a regenerative medicine company with a technology platform positioned to address unmet medical needs in burns, chronic wounds, and aesthetics indications. AVITA Medicals patented and proprietary collection and application technology provides innovative treatment solutions derived from the regenerative properties of a patients own skin. The medical devices work by preparing a RES REGENERATIVE EPIDERMAL SUSPENSION, an autologous suspension comprised of the patients skin cells necessary to regenerate natural healthy epidermis. This autologous suspension is then sprayed onto the areas of the patient requiring treatment.

AVITA Medicals first U.S. product, the RECELL System, was approved by the U.S. Food and Drug Administration (FDA) in September 2018 and a new ease-of-use design was approved in 2022. The RECELL System is indicated for use in the treatment of acute thermal burns. The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patients own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care alone or in combination with autografts depending on the depth of the burn injury. Compelling data from randomized, controlled clinical trials conducted at major U.S. burn centers and real-world use in more than 10,000 patients globally reinforce that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings. Healthcare professionals should read the INSTRUCTIONS FOR USE - RECELL Autologous Cell Harvesting Device (https://recellsystem.com/) for a full description of indications for use and important safety information including contraindications, warnings, and precautions.

In international markets, our products are marketed under the RECELL System brand to promote skin healing in a wide range of applications including burns, chronic wounds, and aesthetics. The RECELL System is TGA-registered in Australia and received CE-mark approval in Europe. To learn more, visit http://www.avitamedical.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as anticipate, expect, intend, could, may, will, believe, estimate, look forward, forecast, goal, target, project, continue, outlook, guidance, future, other words of similar meaning and the use of future dates. Forward-looking statements in this press release include, but are not limited to, statements concerning, among other things, our ongoing clinical trials and product development activities, regulatory approval of our products, the potential for future growth in our business, and our ability to achieve our key strategic, operational and financial goal. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the timing of regulatory approvals of our products; physician acceptance, endorsement, and use of our products; failure to achieve the anticipated benefits from approval of our products; the effect of regulatory actions; product liability claims; risks associated with international operations and expansion; and other business effects, including the effects of industry, economic or political conditions outside of the companys control. Investors should not place considerable reliance on the forward-looking statements contained in this press release. Investors are encouraged to read our publicly available filings for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this release, and we undertake no obligation to update or revise any of these statements.

This press release was authorized by the review committee of AVITA Medical, Inc.

FOR FURTHER INFORMATION:

O.U.S. MediaRudi Michelson Phone +61 (0)3 9620 3333 Mobile +61 (0)411 402 737 rudim@monsoon.com.au

More:
RECELL System Data to be Presented at the American Burn Association Annual Meeting - GlobeNewswire

"The often-neglected area gets some serious TLCfrom DefenAge6-Week Perfection Neck Cream, an intense, treatment-like cream that has the ability to strengthen fragile skin on the neck," states Santa Monica, CA dermatologist Ava Shamban, M.D., in the NewBeauty Magazine inaugural Award article.

Each year, the NewBeauty Awards showcase the most innovative and noteworthy products with the distinct ability to solve beauty's biggest problems. NewBeauty editors and medical experts rigorously test nearly 10,000 products over six months to hand-pick the top performers in beauty.

With 19 clinical studies to support the safety and efficacy of DefenAge's formulas and Age-Repair Defensins, the 6-Week Perfection Neck Creamsignifies a breakthrough in topical skincare for tightening and moisturizing neck skin. Rich moisturization technologies, combined with the unique mechanism of action of DefenAge's exclusive Defensin-molecules, enable a multiplication effect and lead to quickly appearing results for neck skin that looks firmer, smoother, and more even-toned.

A great retinol alternative, the neck cream addresses brightness, improves the visible thickness of the skin, and reduces the appearance of the wrinkles on the neck where aging is often more noticeable.

With an extended clean beauty profile, the 6-Week Perfection Neck Cream does not contain parabens, fragrances, formaldehydes, and phthalates. A leader in clinically clean beauty, DefenAge is the only physician-dispensed brand that makes both claims 'free from animal- and human- derived ingredients.'

"We are thrilled to receive the NewBeauty honor for the third time," shares Nikolay Turovets, Ph.D., CEO of DefenAge. "The NewBeauty Awards are a leading and trusted program in the beauty space and we're privileged to be recognized as skincare technology leaders by NewBeauty editors, physicians, and readers."

Theneck tightening creamretails online on the brand's website,defenage.com, and through dermatologists and aesthetic surgeons, med spas, and other professional aesthetic service providers.

About DefenAge:DefenAge is an American company founded in 2014 by a team of regenerative medicine experts whose anti-aging discovery became the heart and soul of its formulas. DefenAge's products are widely recommended by dermatologists as a high-performing, anti-aging cosmetic skincare for visible skin rejuvenation and as a safe alternative for retinol. DefenAge complies with or exceeds the Clean Beauty standards and its products have never been tested on animals. Honesty, transparency, and excelling in every way possible are the company's standards.

http://www.defenage.com@defenageskincare

CONTACT:KELZ MEDIASheila McCrink[emailprotected] (646) 450-5359 @KELZPR

SOURCE DefenAge

Continued here:
DefenAge 6-Week Perfection Neck Cream Named NewBeauty Award Winner - PR Newswire